GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
AI-powered cardiometabolic wellness platform for India’s workforce
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
Subscribe To Our Newsletter & Stay Updated